



### Exploring Clinical Trials Acceleration: ATTC Industrial Advisory Group Meeting 20.9.21

Organisation: Cell and Gene Therapy Catapult and Advanced Therapies Treatment Centre network

Document version number: 1.

Date written: 20.9.21

### **End user rights:**

This document is shared with permission for re-use to distribute, remix, adapt, and build upon the material in any medium or format for non-commercial purposes only, so long as the attributions listed below are given.

**Attributions:** Cell and Gene Therapy Catapult and Advanced Therapies Treatment Centre network

This document is made available under a Creative Commons Attribution-NonCommercial 4.0 International License as described here:

https://creativecommons.org/licenses/by-nc/4.0/

The information, materials and any opinions contained in this document are provided for general information and educational purposes only, are not intended to constitute legal, medical or other professional advice and should not be relied on or treated as a substitute for specific advice relevant to particular circumstances. Although we make all reasonable efforts to ensure the information is up to date, we make no representations, warranties or guarantees in that regard.

**Funded by** 









In no event shall the creator(s) be liable for any direct, indirect, special, consequential or other claims, losses or damages that are related to the use or reliance whatsoever in the content of the document or any part thereof, except to the extent that such liability cannot be excluded by law. We do not seek to exclude or limit in any way our liability to the user for personal injury or death caused as a result of our negligence or seek to exclude or limit our liability for fraud or fraudulent misrepresentation by us.

We reserve the right to make changes and improvements to any information contained within this document, at any time and without notice. Where this document contains hyperlinks to other websites operated by parties not connected to us, such hyperlinks are provided for your reference only. We do not control such websites and are not responsible for their contents. The inclusion of hyperlinks from this document or the website to such websites does not imply any endorsement of the material on such websites or any association with their operators. We accept no responsibility of any nature whatsoever for linked web sites or any information contained in them.

Funded by







## Industry Advisory Group Meeting 20th SEP 2021


# Breakout Room 1: Exploring Clinical Trials Acceleration

What are the major barriers to effective ATiMP clinical trial set up


and recruitment? Institutional correct roles within site to Appropriate properly enact signatories ATMPs Quality Technical Agreement appropriate site rep Cost - Highly Patient qualified staff identification & used at site effective screening (increase set up fee) Screening fatigue - site investment in infrastructure to screen Accurate Limited feasibility availability data from ATiMP sites RECs Competing Trials

What needs to change to overcome

What are the key metrics for ATiMP these barriers? clinical trials set up?



# Analysis + Takeaways



## Barriers: ATMP clinical trial infrastructure, knowledge, experience must increase with an eye to reducing

### Changes: greater clarity and transparency around how sites set up and conduct ATiMP trials with bench marking from other countries to ensure competitiveness

### Metrics: The "Traditional" metrics are required to enable comparision between ATiMPs & other research. However, concurrent metrics sympathetic to the ATMP being tracked also give important insights

Any action must ensure the UK is a competitive place to